‘The Constant Gardener’: What the Movie Missed

‘The Constant Gardener’: What the Movie Missed

‘The Constant Gardener’: What the Movie Missed

As Big Pharma increasingly turns to the Third World to test its products, this lush film will spark outrage, but glosses over the constant vigilance necessary to police drug trials.


A lush, atmospheric drama, The Constant Gardener brings unprecedented exposure to crucial issues facing the Western pharmaceutical industry and all those who partake of it. Set mostly in a sun-dappled Kenya and based on a John le Carré thriller, the film is a fierce but flawed indictment of Big Pharma’s complicity in African illness and poverty.

The film revolves around the transformation of mild-mannered career diplomat Justin Quayle, played by Ralph Fiennes. Quayle’s wife, Tessa, played by Rachel Weisz, has exposed a botched experimental trial conducted by a Western drug company upon unsuspecting African villagers. After she is found mysteriously murdered, Justin is infected with his firebrand wife’s righteous indignation.

The plot couldn’t be more timely. According to a May 16 report in USA Today, giant drug outfits are outsourcing increasing numbers of drug trials outside the United States and Europe. Merck is now conducting 50 percent of its trials outside the United States. By 2006, 70 percent of Wyeth Pharmaceuticals trials are expected to occur offshore. Across Latin America, Eastern Europe, Asia and Africa, the sick are abundant, desperate and doc-trusting, and so recruitment into clinical trials is rapid. As one executive from an outfit specializing in running drug trials in Asia put it, patients in developing countries are “more willing to be guinea pigs.”

As the film makes all too clear, Big Pharma’s new experimental bodies in the developing world only rarely enjoy the benefits of the research they participate in. Sometimes the new drugs are unlicensed in their countries or priced out of reach, but more often the drugs are irrelevant to the medical needs of their communities. After all, 90 percent of the global medical research budget takes aim at illnesses that cause just 10 percent of the world’s disease burden. And so, while 500 million cases of malaria rage across the developing world, the working poor of India, South Africa and elsewhere, desperate for the kind of high-tech care available to them almost solely through clinical research, line up for experimental doses of the latest arthritis, heart disease and obesity drugs.

Not surprisingly, ethical lapses are strikingly common. In one inquiry, out of thirty-three subjects enrolled in an experiment trial in Thailand, all of whom had signed forms stating their informed consent, thirty were found to be dangerously misinformed. The experimental HIV vaccine they were about to receive had no known protective value, but, according to the subjects, it would, in fact, protect them from the deadly virus. “Informed consent is a joke,” said one industry researcher in an anonymous survey sponsored by the National Bioethics Advisory Commission.

But challenging these practices is not nearly as black-and-white as this film would have it. Tessa Quayle, the martyred activist, stands up to yell “bullshit” at public lectures, shaking her lovely dark mane while she’s at it. At cocktail parties, she loudly embarrasses the health minister, who marches off in a huff. Good stuff, but the reality is that uncompromising activists–even if they look like Rachel Weisz–rarely enjoy this kind of privileged access to power so effortlessly. Tessa has it too good and too bad, too. She ends up paying with her life for her exposure of the botched trial; in real life, bad drugs and unethical research practices often continue unhindered despite mountains of data and reports detailing their defects.

As I found while researching a book on the topic, experimental protocols that would be condemned as unethical in the West–including placebo trials among ailing AIDS patients–are frequently described in the medical press; when the subjects are poor Africans or Asians, nary an eye is batted. (Recall that papers describing this country’s most egregious scientific study, the Tuskegee Syphilis Study, in which government doctors denied treatment to black syphilitics, regularly appeared in the medical press from the 1930s onward. That study wasn’t terminated until 1972.)

In the film, the trial’s results are so dangerous that they must be suppressed by an international conspiracy of corporate execs and state authorities. If only. The trouble is that most of the time new drugs aren’t uniformly deadly, rendering unequivocal data showcasing their killer properties. Rather, new drugs do work, just not very well, or not for everyone, or not without side effects or, most frequently, not any better than older, safer drugs. What that means is that challenging unethical trials requires more than wrenching a few critical reports from official dustbins.

Most disappointing, perhaps, is that the film tells us precious little about the explosive trial at its center, despite the fact that the entire plot hinges on its wickedness. Some of the African subjects died in the trial, the film tells us, but little else is revealed. There’s a reason for this strange omission. Most Western audiences will easily jump to the conclusion that any experiment that rendered any deaths is irredeemable, no matter the condition of the patients, the purpose of the trial or the rates of deaths from traditional therapies or no therapy. And yet the business of testing experimental drugs in humans is a risky one, no matter what the condition or drug. Humane research practices may minimize the risks, which must be balanced against potential benefits, but the risks remain, regardless. As one HIV researcher put it, “I mean, shit, we learn by climbing over the bodies of humans.”

That the film makes no allowance for this reality is more than a problem of accuracy. Our reluctance to acknowledge the risks of drug development is the single biggest reason why drug companies have fled the empty test clinics of the United States and Western Europe to set up shop in Africa, Asia, Eastern Europe and Latin America in the first place. On average, every American buys more than ten prescription drugs every year, and yet most are loath to participate in the clinical trials that make new drugs possible. Less than one in twenty Americans take part in experimental trials, with half the American public maligning test subjects as “guinea pigs,” according to a June 2004 Harris poll.

The logical outcome of this “all gain, no pain” attitude toward modern drugs is for drug companies to shift the burden of experimentation away from Western consumers and onto the world’s poor–with all the moral quandaries, ethical lapses and egregious violations that inevitably follow. To paraphrase the rousing finale of The Constant Gardener, we enjoy the benefits of civilization so affordably because their lives are bought so cheaply. To end the cycle, we must own up to the risks of developing new drugs, and decide together how much we are willing to take on and who shall pay the price.

Thank you for reading The Nation!

We hope you enjoyed the story you just read, just one of the many incisive, deeply reported articles we publish daily. Now more than ever, we need fearless journalism that moves the needle on important issues, uncovers malfeasance and corruption, and uplifts voices and perspectives that often go unheard in mainstream media.

Donate right now and help us hold the powerful accountable, shine a light on issues that would otherwise be swept under the rug, and build a more just and equitable future.

For nearly 160 years, The Nation has stood for truth, justice, and moral clarity. As a reader-supported publication, we are not beholden to the whims of advertisers or a corporate owner. But it does take financial resources to report on stories that may take weeks or months to investigate, thoroughly edit and fact-check articles, and get our stories to readers like you.

Donate today and stand with us for a better future. Thank you for being a supporter of independent journalism.

Thank you for your generosity.

Ad Policy